2022
Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2010
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis
Karim Q, Karim S, Baxter C, Friedland G, Gengiah T, Gray A, Grobler A, Naidoo K, Padayatchi N, El-Sadr W. The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal 2010, 100: 808-809. PMID: 21414268, DOI: 10.7196/samj.4621.Peer-Reviewed Original ResearchTiming of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2007
Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies
Friedland G, Harries A, Coetzee D. Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies. The Journal Of Infectious Diseases 2007, 196: s114-s123. PMID: 17624820, DOI: 10.1086/518664.Peer-Reviewed Original ResearchConceptsTB/HIV service integrationHIV service integrationNeeds of patientsPublic health approachWorld Health OrganizationHIV diseaseNational TuberculosisHIV programsHIV interactionsInfection influenceHealth approachSuccessful outcomeTuberculosisDiseaseHealth OrganizationLarge national programProgram settingsSmall demonstration projectsMost settingsOutcomesImplementation of programsProgram collaborationNational programLarge populationService integration
2005
HIV Drug Resistance and HIV Transmission Risk Behaviors Among Active Injection Drug Users
Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. HIV Drug Resistance and HIV Transmission Risk Behaviors Among Active Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 106-109. PMID: 16123691, DOI: 10.1097/01.qai.0000159666.95455.d2.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug-resistant HIVHIV drug resistanceResistant HIVDrug usersRisk behaviorsClinical careActive injection drug usersDrug resistanceHIV transmission risk behaviorsTransmission risk behaviorsInjection risk behaviorsRetrospective studyInjection drugsHIVPrevious monthCareSubstantial numberMultiple partnersDrugsSmall proportionPatientsProportionNeedleMonths
2003
Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians
Schreibman T, Friedland G. Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians. Clinical Infectious Diseases 2003, 36: 1171-1176. PMID: 12715313, DOI: 10.1086/374359.Peer-Reviewed Original ResearchConceptsHIV infectionClinical practiceHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionNew HIV infectionsClinical care sitesPrevention-related activitiesClinical care settingsIntegration of preventionEffective prevention programsPublic health modelFuture prevention activitiesSpecific prevention effortsHIV diseaseVirus infectionCare settingsCare sitesBehavioral counselingClinical careMedical interventionsPrevention programsInfectionPrevention effortsHealth modelPrevention activities
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapy
1987
The Acquired Immunodeficiency Syndrome: General Overview
Friedland G. The Acquired Immunodeficiency Syndrome: General Overview. International Journal Of Neuroscience 1987, 32: 677-686. PMID: 3647936, DOI: 10.3109/00207458709043322.Peer-Reviewed Original Research